Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435955 | 0.98 | — | — | |
| SCHEMBL2180359 | 0.98 | — | — | |
| SCHEMBL1365024 | 0.85 | SMN1; SMN2 (0.44) | TP53 | |
| SCHEMBL2467750 | 0.83 | SMN1; SMN2 (0.43) | TP53 | |
| SCHEMBL29186681 | 0.83 | MMP1 (0.39) | — | |
| SCHEMBL8855146 | 0.82 | MAPT (0.34) | TP53 | |
| SCHEMBL29011998 | 0.82 | MMP1 (0.42) | TP53 | |
| SCHEMBL27814945 | 0.80 | NAAA (0.39) | — | |
| SCHEMBL11830727 | 0.80 | OR51E2 (0.39) | — | |
| SCHEMBL888114 | 0.79 | CA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4030921-B1 | WHEY-BASED NUTRITIONAL COMPOSITIONS FORTIFIED WITH CALCIUM | NESTLE SA (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-115960379-A | Preparation method and application of antibacterial polylysine film | 天津理工大学 | 2023-04-14 | — | — | CN | claimed |
| EP-2094097-B1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER NV (NL) | 2014-02-12 | — | — | EP | claimed |
| EP-2094097-A1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER N.V. (NL) | 2009-09-02 | — | — | EP | claimed |
| US-20080268131-A1 | Edible aerated oil-and-water emulsion | CONOPCO INC, D/B/A UNILEVER | 2008-10-30 | — | — | US | claimed |
| WO-2008080738-A1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER N.V. (NL) | 2008-07-10 | — | — | WO | claimed |
| US-6129925-A | Container filled with infusion liquids and infusion preparation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | claimed |
| US-12035861-B2 | Fibrous structures comprising particles and methods for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240173235-A1 | PERSONAL CARE COMPOSITIONS COMPRISING SILAHYDROCARBONS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2024-05-30 | — | — | US | disclosed |
| US-11970789-B2 | Filaments comprising an active agent nonwoven webs and methods for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117957018-A | Pharmaceutical composition and application thereof | 苏州亚盛药业有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11944693-B2 | Method for delivering an active agent | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| US-11944696-B2 | Detergent product and method for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20080268131-A1 | Edible aerated oil-and-water emulsion | CONOPCO INC, D/B/A UNILEVER | 2008-10-30 | — | — | US | disclosed |
| WO-2008080738-A1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER N.V. (NL) | 2008-07-10 | — | — | WO | disclosed |
| EP-1849008-A1 | SENSOR MOLECULES INCORPORATING A BORONIC ACID SENSOR GROUP | Cambridge Enterprise Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| EP-1699421-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | Chiron Corporation (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006079843-A1 | SENSOR MOLECULES INCORPORATING A BORONIC ACID SENSOR GROUP | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| WO-2005046589-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12035861-B2 | Fibrous structures comprising particles and methods for making same | FGB, CD68, SDCBP | TP53 270/4885 |
| US-11944696-B2 | Detergent product and method for making same | DAGLA, LIPA, DAGLB | TP53 2093/4885 |
| US-11970789-B2 | Filaments comprising an active agent nonwoven webs and methods for making same | VCL, KRT18, TPM4 | TP53 2809/4885 |
| US-11944693-B2 | Method for delivering an active agent | ACTB, KRT18, ACTN1 | TP53 3673/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | TP53 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.